Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Colan Totte Co's Debt-to-EBITDA or its related term are showing as below:
During the past 7 years, the highest Debt-to-EBITDA Ratio of Colan Totte Co was 2.24. The lowest was 0.00. And the median was 0.26.
TSE:7792's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.63 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Colan Totte Co Debt-to-EBITDA Related Terms
Colan Totte Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Colan Totte Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7792 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Colan Totte Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Colan Totte Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Colan Totte Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Colan Totte Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Colan Totte Co (TSE:7792) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Colan Totte Co. According to the industry distribution chart, Colan Totte Co ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Colan Totte Co's Debt-to-EBITDA too high?
Colan Totte Co's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Colan Totte Co ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Colan Totte Co has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Colan Totte Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Colan Totte Co ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Colan Totte Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Colan Totte Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Colan Totte Co's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colan Totte Co stock overvalued right now?
Based on GuruFocus' analysis, Colan Totte Co (TSE:7792) is currently considered Fairly Valued. The stock's GF Value™ is 円1,561.94, compared to a current price of 円1,445.00 — trading 7.5% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Colan Totte Co's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Colan Totte Co (TSE:7792), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Colan Totte Co (TSE:7792) Overvalued in 2026?
Based on GuruFocus' analysis, Colan Totte Co stock appears to be undervalued.
The current stock price of 円1,445.00 is trading 7.5% below its estimated GF Value™ of 円1,561.94.
GuruFocus considers Colan Totte Co to be Fairly Valued.
Key valuation signals for TSE:7792:
Debt-to-EBITDA: 0.00
GF Value™: 円1,561.94 vs. price of 円1,445.00 (7.5% below fair value)
No single metric tells the full story. See the TSE:7792 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Colan Totte Co Ltd is engaged in the manufacturing and sales of medical devices and health products. It divides its business into two segments: Colantotte Business is the brand that develops home magnetic therapy devices, which are the core of the company; and CSS Business is a service that connects people with their families, realizing contacting designated emergency contacts based on the desire to protect loved ones.
90GF Score
Get the complete analysis for TSE:7792
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7792 has been successfully added to your 
